CoronaryAtlas logo
CoronaryAtlas
AMPK
Pathway / Off-pathway / systemic markers

AMPK

protein

AMPK decline impairs metabolic stress response and cardioprotection, contributing to energy depletion and inflammatory dysregulation post-MI.

Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencelow
RationaleMetabolic stress and cardioprotective signaling; off-pathway metabolic regulator.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresNon-Type-I-associated
R — rupture / Type-I
0
C — non-Type-I
67
A — assay feasibility
68
E — evidence strength
55
T1DI (composite)
6
Specificity differential (R−C)-66.7
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmiamag 2
2hypoxemia / respiratory failuremag 2
2hypertensive emergencymag 2
2high-demand / peri-operative stressmag 2
3sudden cardiac deathn/a
4aPCI-related periproceduralmag 2
4bstent thrombosisn/a
4cin-stent restenosismag 2
5CABG-relatedmag 2
Coverage: 8/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 26 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(8)